Isu Abxis Co Ltd
KOSDAQ:086890
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4 930
7 900
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Isu Abxis Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | KR |
Market Cap | 177.3B KRW |
Gross Margin |
72%
|
Country | FR |
Market Cap | 6T USD |
Gross Margin |
0%
|
Country | US |
Market Cap | 320.1B USD |
Gross Margin |
67%
|
Country | US |
Market Cap | 147.4B USD |
Gross Margin |
60%
|
Country | US |
Market Cap | 119.4B USD |
Gross Margin |
86%
|
Country | US |
Market Cap | 113.8B USD |
Gross Margin |
78%
|
Country | US |
Market Cap | 94.1B EUR |
Gross Margin |
76%
|
Country | AU |
Market Cap | 135.4B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 82.6B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 39.3B EUR |
Gross Margin |
75%
|
Country | NL |
Market Cap | 34.3B EUR |
Gross Margin |
89%
|
Isu Abxis Co Ltd
Glance View
ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Isu Abxis Co Ltd's most recent financial statements, the company has Gross Margin of 72.3%.